Secondary prophylaxis in an adult patient with severe haemophilia A Factor VIII consumption and effectiveness

被引:2
|
作者
Schlenkrich, S. [1 ]
Schubert, C. [1 ]
机构
[1] HELIOS Clin Ctr Erfurt, Erfurt, Germany
来源
HAMOSTASEOLOGIE | 2013年 / 33卷 / 03期
关键词
Haemophilia; secondary prophylaxis; adult; bleeding rate; factor VIII consumption;
D O I
10.5482/HAMO-12-07-0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary prophylaxis has been proven as the gold standard for preserving joint function in severe haemophilia. Secondary prophylaxis in children has also been shown to have a more beneficial effect on joint protection as on-demand treatment. The outcome of delayed secondary prophylaxis started in adulthood is rarely studied. The case of a man (age: 47 years) with severe haemophilia A demonstrates the successful switch from on-demand therapy to prophylaxis with subsequent reduction of annual bleeding rate and number of days of work lost. The small increase of factor VIII consumption (16%) and the decrease of bleeding rate are compared with data from two recently published prospective studies. Conclusion: An optimal dosing schedule needs to be discussed and larger and longer prospective studies targeting the benefits of secondary prophylaxis with factor VIII started in adulthood are necessary.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 50 条
  • [1] Optimizing efficacy of factor VIII prophylaxis for severe haemophilia A
    Fischer, K.
    HAEMOPHILIA, 2011, 17 : 9 - 15
  • [2] Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices
    Walsh, C. E.
    Valentino, L. A.
    HAEMOPHILIA, 2009, 15 (05) : 1014 - 1021
  • [3] COST EFFECTIVENESS ANALYSIS EVALUATING FACTOR VIII AS PRIMARY PROPHYLAXIS TREATMENT FOR PATIENTS WITH SEVERE HAEMOPHILIA A IN THE NETHERLANDS
    Kip, M.
    van den Bosch, M.
    Fischer, K.
    Tamminga, R.
    Lepage-Nefkens, I
    VALUE IN HEALTH, 2014, 17 (07) : A531 - A531
  • [4] Prophylaxis with FEIBA in an adult patient with severe haemophilia B and inhibitor
    Klamroth, R.
    Orlovic, M.
    Kubicek-Hofman, C.
    Gottstein, S.
    HAMOSTASEOLOGIE, 2010, 30 (4A): : S56 - S56
  • [5] Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice
    Mingot-Castellano, Maria E.
    Gonzalez-Diaz, Laura
    Tamayo-Bermejo, Rocio
    Heiniger-Mazo, Anabel I.
    BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (05) : 509 - 514
  • [6] The overall effectiveness of prophylaxis in severe haemophilia
    Panicker, J
    Warrier, I
    Thomas, R
    Lusher, JM
    HAEMOPHILIA, 2003, 9 (03) : 272 - 278
  • [7] Incidence of factor VIII inhibitors in severe haemophilia:: the importance of patient age
    Lorenzo, JI
    López, A
    Altisent, C
    Aznar, JA
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 600 - 603
  • [8] Prophylaxis in adult patients with severe haemophilia A
    Oldenburg, Johannes
    Brackmann, Hans-Hermann
    THROMBOSIS RESEARCH, 2014, 134 : S33 - S37
  • [9] Immune Tolerance Induction in A Patient with Severe Haemophilia A and Factor VIII Inhibitors
    Freiria Alberte, C.
    Legarda, M.
    Cid, A. R.
    Guarin, A. P.
    Querol Fuentes, F.
    Bonanad Boix, S.
    Haya Guaita, S.
    HAEMOPHILIA, 2017, 23 : 47 - 48
  • [10] Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
    Megias-Vericat, J. E.
    Bonanad, S.
    Haya, S.
    Cid, A. R.
    Marques, M. R.
    Monte, E.
    Perez-Alenda, S.
    Bosch, P.
    Querol, F.
    Poveda, J. L.
    THROMBOSIS RESEARCH, 2019, 174 : 151 - 162